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Abstract 
Background: Spinal cord injury (SCI) results in impaired function and ankle joint spasticity is a 
common secondary complication. Different interventions have been trialed with variable results.  
Objective: We investigated the effects of pharmacological and physical (locomotor training) 
interventions on function in people living with incomplete motor function loss due to SCI, and 
used different analytical techniques to understand whether functional levels affect recovery with 
different interventions.  
Methods: Participants with an incomplete SCI were assigned to three groups; no intervention, 
Lokomat or tizanidine. Outcome measures were the 10-meter walk test (10MWT), 6-minute 
walk test (6MWT) and the Timed-up and go (TUG). Participants were classified in two ways; i) 
based on achieving an improvement above the minimally important difference (MID) and; ii) 
using Growth Mixture Modeling (GMM). Functional levels of participants that achieved the 
MID were compared and Random Coefficient Regression (RCR) was used to assess recovery in 
GMM classes.   
Results: Overall, walking speed and endurance improved, with no difference between 
interventions. Only a small number of participants achieved the MID. Both MID and GMM-
RCR analyses revealed that tizanidine improved endurance in high functioning participants. 
GMM-RCR classification also showed that speed and mobility improved after locomotor 
training. 
Conclusions: Improvements in function were achieved in a limited number of people with SCI. 
Using the MID and GMM techniques, differences in responses to interventions between high and 
Page 2 of 333 
 
low functioning participants could be identified. These techniques may therefore have potential 
to be used for characterizing therapeutic effects due to different interventions. 
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Introduction 
Rehabilitation for people that are living with spinal cord injury (SCI) is focused on optimizing 
function. One secondary consequence of SCI is neuromuscular abnormalities, resulting in 
hypertonia or spasticity of muscle groups, and has been noted as the main self-reported 
secondary complication after SCI 
1. Spasticity commonly affects the muscles surrounding the 
ankle joint, which have important roles during functional tasks 
2. During gait for example, the 
gastrocnemius, an ankle extensor, is important for propulsion during the stance phase, and the 
tibialis anterior for foot clearance during the swing phase. In people living with SCI, there is 
controversy regarding the relationship between hypertonia and gait function. Severe extensor 
spasticity of gastrocnemius, blocking flexion movements, can impede locomotor ability, and 
some studies have demonstrated that increased hypertonia relates to impaired function 
3-5. Others 
however, have demonstrated no functional improvements with reduced hypertonia, based on 
clinical observations 
6,7.  
Tizanidine, an antispasticity medication, has been shown to reduce hypertonia in SCI individuals 
8-11. As an α2 noradrenergic agonist, it is thought to reduce hypertonia through depression of 
dorsal horn interneuron excitability 
12. While studies commonly report the effects of such 
antispasticity medications on muscle spasticity, assessed by clinical scores 
8,13 or 
electromyographic activity 
13,14, they rarely report effects on the patient’s functional ability 
15. 
The few studies that did report more functional measures demonstrated that Tizanidine 
substantially reduced reflex mechanical responses in SCI individuals 
16, and facilitated locomotor 
capacity in spinalized cats 
17, whereas one study reported that it had no effect on muscle strength 
or activities of daily living in SCI individuals 
8.  
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An alternative intervention that became popular in SCI rehabilitation to improve function is 
Locomotor treadmill training (LTT). LTT, incorporating body-weight supported training and 
robotic-assistive step training, provides gait assistance and body weight support to a patient on a 
motorized treadmill, which aims to improve locomotor function 
18. LTT is thought to improve 
function through the responsiveness of central pattern generators to afferent stimuli noted in 
mammalian quadrupeds 
18,19. In people with chronic SCI, studies have reported that LTT training 
improves overground walking speed 
20-24 and endurance 
22, muscle strength 
23,25,26, corticospinal 
tract function 
25, postural alignment 
20, coordination of electromyographic activity 
20 and 
subjective well-being 
27 
23. It has also been reported to reduce abnormal neuromuscular activity 
(spasticity), measured by clinical scores 
28 or electromyographic activity 
29, although these 
changes did not correlate with functional improvements 
28. Some authors however believe that 
the evidence for LTT is limited 
30 since studies often omit control and alternative intervention 
groups, and those that do include alternative interventions have found similar improvements 
from  conventional physical therapy and overgound walking training 
23,24,31. Similar findings 
have been reported from randomized trials in people with acute SCI 
32.  
Overall, the observed extents and rates of improvement in functional performance from 
interventions after chronic incomplete SCI tend to be variable 
30. In addition, the population of 
people living long-term with incomplete SCI is heterogeneous in terms of their functional 
capacities. The combination of these factors results in commonly employed group-averaging 
techniques showing only small overall improvements 
30, which may mask important data. Some 
SCI individuals may respond to specific treatments whereas others do not; identifying those that 
do respond and understanding how they differ from non-responders is key.  For example, one 
study reported that a greater proportion of more impaired participants with SCI, classified by 
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Lower Extremity Motor Scores (LEMS), improved walking speed after locomotor training, when 
compared with less impaired participants 
24. Whereas other studies have reported greater 
improvements in walking speed with LTT in participants with greater baseline muscle strength
33 
or in those that have the ability to ambulate prior to the intervention
34. Determining whether 
individuals living with SCI respond to interventions differently, according to their baseline 
functional level, may allow us to recommend optimal interventions on a case-by-case basis. 
In order to assess the subjects that did or did not respond to the intervention, it is necessary to 
firstly define the amount of change required for any improvement to be considered real (i.e. 
greater than change due to variation or measurement error), and secondly to define the amount of 
change for the improvement to be considered ‘clinically’ meaningful. That is, a small but 
statistically significant improvement may be irrelevant clinically if it does not impact the 
individual’s quality of life, particularly if the intervention is substantially costly in terms of time, 
effort and/or side effects for the individual. Previously, Beckerman et al.
35 proposed the small 
real difference (SRD) approach, which refers to the smallest possible value required to be 
considered a true difference; thus the minimally important clinical difference must always be 
greater than the SRD for a measurement technique to be valid
35.  Subsequently, Lam et al. 
36 
proposed SRDs for a number of outcome measures commonly used in the population of 
individuals living with SCI. While these values may be useful in assessing those people that 
responded to treatment, it should be acknowledged that they were based on a small number of 
heterogeneous individuals with incomplete SCI, and only account for the variability in the 
measurement technique rather than a change that may be considered clinically relevant or 
regarded as a minimal important difference (MID) to the individual.  
Page 6 of 337 
 
An alternative method of classifying responders from non-responders is growth mixture 
modelling (GMM). GMM is used widely in psychological and educational research to capture 
heterogeneity in developmental pathways, and has recently been applied to recovery patterns in 
rehabilitation research. The technique attempts to classify participants into latent classes 
according to their baseline scores and recovery trends. This may be useful in rehabilitation by 
accounting for some of the inherent variability in individuals and individual responses, by 
considering each individual’s baseline function, as well as their recovery trend in response to the 
intervention. In the future rehabilitation practitioners may use this information to predict, with a 
known confidence level, whether or not a new patient will respond positively to an intervention 
based on their baseline clinical scores. This technique has successfully classed stroke survivors 
based on their recovery patterns 
37.  
The aims of the study were to determine and compare the effects of two different interventions, 
LTT and tizanidine, on gait impairments, using a commonly employed group-averaging 
technique, MID and GMM techniques. We hypothesized that differences in responses to 
interventions would not be detected by ANOVA and both MID and GMM techniques would 
identify different responses to the interventions in high compared with low functioning 
participants, assessed by WISCI II scores and baseline outcome measures. 
Methodology 
Participants 
Participants with either cervical or thoracic incomplete spinal cord injury, as a result of trauma, 
were recruited from the outpatient service at the Rehabilitation Institute of Chicago. All 
participants provided written informed consent and the study had ethical approval from the 
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Northwestern University Institutional Review Board. Inclusion criteria were aged 18-50 years, 
motor incomplete SCI (ASIA impairment scale [AIS] classification C or D) with level of injury 
above T10 and >12 months post injury, ambulatory, medical clearance to participate, evidence of 
clinical spasticity in the ankle joint (Modified Ashworth Score (MAS) >1), and lower-limb 
passive range of motion within functional limits for ambulation. Exclusion criteria were sitting 
tolerance <2 hours, existing infection, severe cardiovascular or pulmonary disease, concomitant 
neurological injury, history of fractures post-SCI, known orthopedic or peripheral nerve injury in 
the lower extremities. The Walking Index for Spinal Cord Injury II (WISCI II) assessment was 
initially carried out to assess the participants walking ability (level of functional impairment). 
Participants were then randomized into one of three intervention groups; no intervention 
(control; n=29), LTT (Lok; n=27) and Tizanidine (Tiz; n=27). Subject characteristics are 
provided in Table 1. 
 
Interventions 
Interventions were given for 4 weeks in the Lok and Tiz groups. Control participants received no 
intervention. Participants taking muscle relaxant medications prior to enrolling on the study were 
tapered from their medication prior to the start of the study. Participants were requested not to 
alter their current medications otherwise, where possible, and to inform us of any changes in 
their medications during the intervention. 
For the Lok group, locomotor training was provided using a robot-assisted locomotor training 
device (Lokomat, Hocoma AG, Switzerland). This device provides body-weight supported gait 
assistance; the individual is suspended in a harness over a motorized treadmill while the frame of 
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the robot, attached by straps to the outside of the lower limbs, moves the limbs in a natural 
walking pattern. 
Training was provided three times per week; each session lasted <1 hour, with 30-45 minutes of 
training.  Treadmill speed, body-weight support and robotic guidance force was determined by 
the physical therapist, based on tolerance and comfort of the subject. Generally however, 
reducing guidance force was prioritized to promote voluntary drive to muscles, and to minimize 
passive training. Body-weight support was configured to maximize lower-extremity loading 
without producing excessive knee flexion during the stance phase, or allowing toe-drag during 
the swing phase.  Participants were instructed to “walk with the robot” to ensure that the lower-
extremity movements were consistent with the Lokomat stepping pattern. Participants were also 
instructed to pay attention to their ankle movements during the gait cycle i.e. to focus on planting 
the heel of their foot at heel-strike and to “lift their toes” during the swing phase.  A mirror 
placed in front of the participants provided visual feedback.  
For the Tiz group, .03 mg/kg of Tizanidine was administered four times a day for four weeks. 
This dosage represents a useful compromise, in that it usually shows efficacy
16, but does not 
cause overwhelming side effects. In the first week, administration of the drug was progressively 
increased until the full dosage was received on day 7, and the full dosage was then administered 
for a subsequent 4-week period. 
Outcome measures 
Outcomes were measured at four time points: baseline and 1, 2 and 4 weeks into the intervention 
(or after baseline for controls). For the Tiz group, outcome measures were taken at baseline and 
1, 2 and 4 weeks after the participants Tizanidine had been regulated. 
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Functional measures included; i) the 10-meter walk test (10MWT) whereby participants are 
instructed to walk 10 meters as quickly and safely as possible, and time is measured 
38-40; ii) the 
6-minute walk test (6MWT) whereby participants are instructed to walk for 6 minutes and the 
distance covered is measured
40 and; iii) the Timed up and go (TUG) whereby participants are 
instructed to stand up from an armed chair, walk 3 meters, turn, return to the chair and sit down, 
and time is measured
40. 
Data Analysis 
Statistical tests were carried out using SPSS (SPPS v21, IBM Corp, USA), and p<0.05 was 
considered significant. One way analysis of variance (ANOVA) was used to assess differences in 
subject’s age, time since injury and functional level between the three intervention groups.  
Two way mixed design ANOVAs were used to identify significant changes due to time-point 
(within-subject) and group (between-subject) for the three groups.  
Data were classified for each task using two methods:  
i)  According to whether or not they achieved the MID for each test. The MID was 
defined using control group data; this was calculated as proposed by Beckerman et al 
35 (1.96*√2*SEM).   Participants that achieved a change from baseline equal to or 
greater than the MID for that test, after 4 weeks of training, were classified as ‘MID 
achieved’, and those that had a change from baseline less than the MID for that test 
were classified as ‘MID not achieved’. Differences in MAS and WISCI II scores 
among the three intervention groups for those that did achieve the MID for each test 
were assessed using one way ANOVAs. Within each group, differences in WISCI II 
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scores between those that did and did not achieve the MID for each test were assessed 
using independent sample T-Tests. 
ii)  Growth mixture modelling (GMM) can be used to identify sub-populations within a 
group that demonstrate similar longitudinal change or growth (for a basic review 
see
41). The model assumes that the population can be separated into a finite number 
of classes that are similar, in a post-hoc manner (i.e. does not include a priori 
knowledge of how the data should be classed). The model estimates the probability 
that each individual should belong to each class, and then classifies that individual 
into the class that they are most likely to belong.  
Using R software (R v2.15, R Systems, India) a given number of classes (2, 3 or 4) 
were generated by the model according to baseline data and recovery slope trends. 
For the recovery trend, we forced the model to define the pattern linearly, which can 
be represented by a single slope, as this was adequate to describe the relationship. The 
model with the best fit was accepted for the final classification. This was carried out 
separately for each outcome measure and group.  Subsequently, Random Coefficient 
Regression (RCR) was used to assess whether or not each GMM class improved 
significantly with time, as a result of the intervention. The RCR method is intended to 
be a substitute for repeated-measures ANOVA, with the presence of a random effect 
indexed on subject number for the time factor. The RCR is also more capable to 
model nonlinearities in the trend. 
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Results  
Participants 
There were no significant differences between the participants in each intervention group in 
terms of age, time since injury WISCI II scores and MAS (Table 1; p>0.05 for all variables). 
Two participants in the control group did not complete the study and one participant in the Tiz 
group was not able to complete the clinical measures, therefore analysis in the Lok and Tiz 
groups were carried out on n=27 and n=26, respectively. Participants did not report any changes 
to their medications during the intervention. 
Analysis of Variance 
Mixed model ANOVAs revealed significant improvements with time for both walking speed in 
the 10MWT (p<0.001; Fig 1A) and walking distance in the 6MWT (p=0.002; Fig 1B), with no 
group effects or interactions. For TUG, there were no significant effects of either time-point or 
group (Fig 1C). 
Minimal Important Differences 
Based on our control data, MID values were 0.11m/s, 37.1m and -14.5s for the 10MWT, 6MWT 
and TUG, respectively. Participants were classified according to whether or not they achieved 
the MID for each test. Individuals were excluded if either baseline or week 4 data was missing; 
final N values for each group are provided in Table 2. For the 10MWT, the number (proportion) 
of participants that achieved the MID, after 4 weeks of training, were 2 (8%), 4 (15%) and 6 
(23%) for Control, Lok and Tiz groups, respectively. Equivalent values for the 6MWT were 3 
(13%), 2 (8%) and 5 (20%), and 2 (8%), 2 (8%) and 3 (12%) for the TUG (Table 2). Of those 
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that did attain the MID within each test, there was no significant differences in MAS or WISCI II 
scores between the three intervention groups. However, those that attained the MID for the 
6MWT had significantly higher WISCI II scores than those that did not attain the MID within the 
Tiz and control groups (p<0.001; Table 2). This was also true for the 10MWT within the Tiz 
group only (p<0.001; Table 2), with no significant differences observed for the TUG.  
In addition, those participants that achieved the MID for the 10MWT had significantly higher 
baseline walking speeds in both Tiz (p<0.001) and control (p=0.04) groups, and those that 
achieved the MID for the 6MWT had significantly higher baseline walking distance in the Tiz 
group (p<0.001). Finally, those that achieved the MID for the TUG had significantly longer 
times in the control (p=0.04) and Lok (p=0.04) groups. Overall therefore, for the 10MWT and 
6MWT, the participants that attained the MID tended to be higher functioning (Table 2 & Fig 
2A-B), and for the TUG, those that achieved the MID tended to be lower functioning (Table 2 & 
Fig 2C). There were no significant difference in MAS between participants that did and did not 
attain the MID for all interventions and outcome measures (Table 2). 
Growth Mixture Modelling 
Participants were excluded from the analysis if they did not complete any of the tests for a given 
outcome measure; this was only the case for the 6MWT where some individuals were not able to 
walk for 6 minutes duration throughout the study. Final N values for each group are provided in 
Table 3.  The best fit GMM categorized participants for each outcome measure into two classes 
for all groups and outcome measures. Participants in Class 2 had significantly higher WISCI II 
scores and significantly improved baseline scores compared with Class 1, for all outcome 
measures and intervention groups (Table 3). Therefore these classes were considered as high 
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(Class 2) and low (Class 1) functioning. There were no significant difference in MAS between 
participants in Class 1 compared with Class 2 for all interventions and outcome measures (Table 
3). For the 10MWT, RCR revealed significant improvements with time for the Lok group in both 
the higher (Class 2; p<0.01) and lower (Class 1; p<0.05) functioning classes, with no significant 
changes for Tiz or control participants (Fig. 3A). For the 6MWT, significant improvements with 
time were found for the Tiz group in the higher functioning class only (Class 2, p<0.05; Fig. 3B). 
For the TUG, significant improvements with time were also found for the Lok group in the 
higher functioning class only (Class 2, p<0.05).  
Discussion 
This study compared the effects of two different interventions, LTT and tizanidine, on gait 
impairments and used different analytical techniques to understand whether functional levels of 
people with chronic incomplete spinal cord injury affect functional recovery with different 
interventions. Mixed model ANOVAs revealed small improvements in walking speed and 
endurance with no significant differences between the interventions (locomotor treadmill 
training, anti-spasticity medication and control). Using MID analysis, the number of participants 
that achieved the MID was small. Both MID and GMM-RCR analyses revealed improved 
endurance after Tizanidine for high functioning participants only. GMM-RCR analysis also 
revealed significant improvements in walking speed after Lokomat training for both high and 
low functioning participants, and improved mobility for high functioning participants only. 
Using group averaging techniques, we found small improvements in walking speed and 
endurance, with no significant difference between intervention groups. These findings are 
consistent with previous reports, which conclude that small functional changes do occur with 
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LTT, however these changes are similar compared with other physical interventions 
23,24,31. The 
effects of anti-spasticity medications on functional measures have seldom been reported, and 
studies that have reported the effects of other pharmacological interventions, found small to 
negative effects on walking speed 
42, and concluded that locomotor training resulted in better 
outcomes than any of the pharmacological interventions studied 
42. In the present study we found 
small effects from Tizanidine, which were similar compared to the effects of LTT. There was 
large variability in the clinical outcome data for each group (Fig 1), which also agrees with 
previous work 
30, and may relate to the wide variability in functional levels among individuals 
with chronic incomplete SCI.  
Therefore, we considered two alternative analysis techniques; the MID for clinical outcomes 
taken, in order to classify the participants that did or did not attain a real (clinical) change due to 
each intervention, and growth mixture modeling (GMM). From the MID analysis, we noted that 
2-6 participants achieved the MID, depending on the outcome measure and intervention used. 
When comparing the classification of subjects between the two techniques, it was notable that all 
participants classified as achieving the MID for the 10MWT and 6MWT, were also classified as 
Class 2 (high functioning) by the GMM; this was true across all intervention groups. For the 
TUG however, all participants that achieved the MID were classed as low functioning (Class 1). 
Tizanidine improved both walking speed and endurance for the highest number of participants 
attaining the MID across all groups (5-6 participants). These participants were found to have 
significantly higher functional levels than those that did not attain the MID, evidenced by 
significantly higher WISCI II scores (p<0.001), and significantly higher baseline scores 
(p<0.001) for both speed and endurance (Table 2). In agreement, GMM-RCR analysis revealed 
significant improvements in walking endurance due to Tizanidine in Class 2 only; Class 2 were 
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higher functioning subjects evidenced by significantly higher WISCI II (p<0.001) and baseline 
(p<0.001) scores (Table 3), similar to MID analysis. However, significant improvements in 
walking speed were not noted due to Tizanidine in GMM-RCR analysis, which was in contrast to 
MID results. Tizanidine may have reduced spasticity in the gastrocnemius muscle, which 
allowed improved (more co-ordinated) functioning of the tibialis anterior muscle, resulting in 
improved walking function. Further research is required to corroborate this speculation. 
GMM-RCR analysis also revealed improved walking speed in the LTT group only, which was 
irrespective of functional level (a significant improvement was noted for both classes (Fig. 3)). 
MID analysis revealed improved walking speed due to LTT in 4/27 participants, with no 
difference in functional levels between those that did and did not achieve the MID (no difference 
in WISCI II scores or baseline walking speed; Table 2). Improved walking speed with LTT has 
been reported previously 
20-24, and may be the result of improved muscle strength 
23.  The fact 
that the improvement in walking speed was unrelated to functional level, evidenced in both MID 
and GMM-RCR analyses, is in contrast with a previous study that noted a greater proportion of 
more impaired participants with SCI improved walking speed after locomotor training compared 
with less impaired participants 
24. In that study, the lower extremity motor score (LEMS) was 
used to assess impairment level, which assesses lower limb muscle strength, as opposed to 
walking ability, as assessed by WISCI II scores used in the present study. In addition, 
participants trained for a longer period (12 weeks) in the study by Field-Fote & Roach 
24, 
compared with only 4 weeks in our study. Longer duration LTT may have elicited greater 
functional adaptations and may have allowed distinction between functional levels. 
GMM-RCR analysis also revealed a significant improvement in walking mobility (TUG) for 
higher functioning participants only after LTT; however this result was not evident from MID 
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analysis. MID analysis showed that Tizanidine improved mobility in only 3/27 participants, and 
those that achieved the MID tended to be lower functioning (lower WISCI II score and higher 
baseline time to complete the TUG), however these differences were not significantly significant, 
which may be due to the low number of participants that did achieve the MID. As stated 
previously, all subjects that achieved the MID for the TUG were classed as low functioning by 
the GMM (Class 1), therefore the significant improvement in TUG for high functioning 
participants only (Class 2) by GMM-RCR analysis is an unexpected result that opposes the 
results of MID analysis. Such differences between MID and GMM analyses may relate to the 
fact that MID uses only the baseline and final data points, rather than the overall trend as was 
used in GMM analysis; thus the MID approach may be more susceptible to day-to-day 
measurement variations. This does however highlight the importance of the analysis method 
chosen.  Overall, both GMM and MID techniques could identify some different outcomes for 
high vs low functioning participants that could not be detected using analysis of variance 
(ANOVA) alone. 
Spasticity 
Spasticity may both assist and impair gait function. Thus, baseline levels of spasticity at the 
ankle joint may be important in determining which subjects will respond to different 
interventions as opposed to (or as well as) functional levels. We therefore compared ankle joint 
MAS between those subjects that did and did not attain the MID. Our data suggests that 
spasticity level does not impact whether or not each individual will attain the MID. However, it 
has previously been reported that no significant correlation between quantitative measures of 
muscular and reflex torque/stiffness associated with spasticity and the MAS magnitude 
43. Thus, 
while MAS is sufficient to assess the presence of clinical spasticity as measured by overall 
Page 17 of 3318 
 
stiffness (inclusion criteria), it cannot determine the contribution of neuromuscular properties to 
the overall stiffness and thus it may be unreliable as an indicator of spasticity level.  
Knee joint spasticity may also affect gait impairment; in some individuals, particularly those 
with muscle weakness, knee spasticity may assist walking, thus anti-spastic medication may not 
benefit these people, whereas in others it may reduce knee joint spasticity without reducing 
stability at the knee. We cannot speculate from our data whether changes in knee joint spasticity 
influenced the outcomes. 
Clinical Significance 
An unexpected observation from this study was that, overall, the participants that achieved the 
MID for the 10MWT and the 6MWT, tended to be higher functioning for that measure at 
baseline. That is, their baseline walking speed and distances were >0.58m/s and >165m, 
respectively (Fig. 2A-B). In contrast however, it was the lower functioning participants that 
tended to attain the MID for the TUG outcome measure i.e. those with a baseline time of >57s 
(Fig. 2C; note that an increase in time represents lower function with this measure). This was not 
however significant across all groups, which may have been due to the fact that a number of 
participants that did not achieve the MID had similar baseline scores to those that did (Fig. 2A-
C), as well as due to low participant numbers that did attain the MID.  
The TUG assesses mobility, walking ability, balance and risk of falling, as opposed to walking 
speed or endurance, as with the other measures taken. For lower functioning participants it may 
be that an improvement in mobility and balance is required before changes in speed and/or 
endurance take place. Thus the TUG may be a more suitable assessment to detect this change in 
low functioning participants, whereas the 10MWT and 6MWT were more suitable tests for 
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higher functioning participants. This is in agreement with a previous study, which showed the 
10MWT and 6MWT to be more sensitive to change in participants with SCI with higher walking 
proficiency compared with an alternative measure of functional walking tasks (the SCI 
Functional Ambulation Profile, which includes the TUG)
44. 
These finding may also be clinically informative. For example, based on our data, it is indicated 
that individuals with a baseline walking speed of >0.58m/s have a 55% chance of achieving 
improved walking speed after a 4-week Tizanidine intervention (i.e. 6/11 participants that had a 
baseline speed >0.58m/s achieved the MID in that group), and have a 33% chance of achieving 
improved walking speed with 12 sessions of LTT. Whereas those with a baseline walking speed 
of <0.58m/s have little or no chance of showing an improvement with either intervention.  
 For the GMM analysis, subjects were classified using both their baseline scores and recovery 
trends. Therefore, in the groups that showed significant improvements with RCR, the majority, 
but not necessarily all individuals, showed improvements. GMM-RCR results therefore similarly 
allow us to predict, from baseline scores, the likelihood of an individual belonging to a class, and 
thus the probability that the individual will have improved gait function with a given 
intervention. Both techniques may therefore provide useful knowledge to clinicians and patients 
when deciding on the most appropriate intervention for each individual, and provide more 
information than using group averaging techniques such as ANOVAs.  
Limitations 
While GMM-RCR appears to be a useful technique, it should be noted that the significant 
improvements found by RCR were small, and considerably less than our MID values, thus the 
changes due to the interventions may still not be clinically relevant (i.e. may not significantly 
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impact the individuals quality of life). Similarly, for the MID analysis, only a relatively small 
number of subjects (2-6 participants per group) achieved the MID, and this was also the case in 
the control group (i.e. some control participants did attain the MID with no intervention). Thus 
the outcome measures alone may have been sufficient to induce clinically relevant changes in 
some individuals. In a review article, it has previously been shown that the total number of 
training sessions required to improve walking outcomes >MID was 10-130 sessions
45. In this 
study we provided only 12 sessions, which is toward the shorter end of that range.  Therefore, 
providing a greater number of training sessions may have resulted in greater improvements, or 
increased the number of participants that achieved the MID. 
This study was sufficiently powered for the group comparisons using ANOVA’s and for the 
comparisons made between classes for the GMM analysis (>0.80). However, due to the low 
number of subjects achieving the MID, the study was underpowered for some statistical 
comparisons in those groups. In addition, the number of participants within each group that did 
not attain the MID (21-25 individuals) was substantially different to the number that did, which 
also impacts the validity of the statistical tests used. Therefore these results should be interpreted 
with caution, and it is recommended that future studies incorporate a greater number of training 
sessions, which may result in a greater number of participants achieving the MID. A final 
limitation is that the participants in this study were also not followed up; therefore we cannot 
speculate on whether noted changes were long-standing in these patients. Such measures would 
also be beneficial in future studies. 
In conclusion, using group averaging (ANOVA) techniques, small improvements in walking 
speed and endurance occur with interventions in people with chronic SCI; however similar 
results were observed between interventions. Both MID and GMM-RCR analysis revealed 
Page 20 of 3321 
 
improvements in walking endurance with Tizanidine in high function participants only; a finding 
that typical group averaging technique could not detect. GMM-RCR analysis additionally 
revealed improvements in walking speed and mobility with LTT. MID revealed that the TUG 
may be a more suitable assessment for low functioning subjects, and the 10MWT and 6MWT 
may be more suitable for higher functioning subjects. Overall, results of MID and GMM-RCR 
analysis were in agreement for the 10MWT and 6MWT, but disagreed regarding the TUG. These 
findings demonstrate that both GMM and MID analyses have the potential to characterize the 
therapeutic effects of various types of interventions on clinical outcome measures. 
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Table 1. Mean (SD) characteristics of participants in the three groups. F=Female; M=Male; 
WISCI II= Walking Index for Spinal Cord Injury II; MAS=Modified Ashworth Score. 
   Control  Lokomat  Tizanidine 
Gender  10 F; 19 M  8 F; 19 M  8 F; 19 M 
Age (years)  47.8 (13.1)  46.6 (12.6)  47.4 (11.6) 
Time since injury (years)  8.1 (8.1)  9.3 (8.9)  10.9 (10.8) 
WISCI II Score  13.8 (5.8)  14.7 (5.2)  14.9 (4.6) 
Ankle 
MAS  
Left  1.9 (0.8)  1.6 (0.9)  1.5 (0.8) 
Right  1.9 (0.8)  1.9 (1.2)  1.6 (0.9) 
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Table 2. Number (N) of participants and mean (SD) baseline scores, mean (SD) Walking Index 
for Spinal Cord Injury II (WISCI II) scores and Modified Ashworth Scale (MAS) scores for 
participants that did and did not attain the minimal important difference (MID) for the 10 meter 
walk test (10MWT), 6 minute walk test (6MWT) and the Timed Up and Go (TUG) in each group 
(**p<0.001 and *p<0.05 compared with MID not attained within group). 
Score  Clinical 
outcome 
Control  Lokomat (Lok)  Tizanidine (Tiz) 
MID not 
attained 
MID 
attained 
MID not 
attained  
MID 
attained  
MID not 
attained  
MID 
attained  
N 
10MWT  23  2  22  4  20  6 
6MWT  20  3  22  2  20  5 
TUG  24  2  22  2  23  3 
Baseline 
score 
10MWT  0.55 
(0.39) 
0.78 
(0.07)* 
0.47 
(0.34) 
0.99 
(0.43) 
0.43 
(0.32) 
0.82 
(0.16)** 
6MWT  191.6 
(101.1) 
313.9 
(171.2) 
171.6 
(117.0) 
391.9 
(217.3) 
145.5 
(87.8) 
282.5 
(40.0)** 
TUG  33.4 
(28.3) 
71.5 
(11.5)* 
35.4 
(36.1) 
113.0 
(18.4)* 
35.1 
(28.6) 
120.6 
(64.0) 
WISCI 
II 
10MWT  15.1 (4.4)  18.0 (2.8)  14.3 (5.2)  17.0 (5.3)  14.1 (3.0)  19.7 
(0.5)** 
6MWT  15.3 (4.0)  20.0 
(0.0)** 
14.7 (6.0)  14.5 (7.8)  14.5 (3.3)  19.8 
(0.5)** 
TUG  15.4 (4.5)  12.5 (5.0)  16.3 (3.9)  11.0 (2.8)  16.0 (3.4)  11.7 (2.3) 
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MAS 
10MWT  2.0 (0.7)  2.0 (1.4)  2.0 (1.0)  2.0 (0.8)  1.8 (0.8)   1.7 (1.2) 
6MWT  2.2 (0.6)  1.7 (0.6)  2.0 (1.1)  2.5 (0.7)  1.8 (0.9)  1.4 (0.9) 
TUG  2.2 (0.6)  2.5 (0.7)  1.9 (1.0)  2.0 (0.0)  1.8 (0.9)  1.3 (0.6) 
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Table 3. Number (N) of participants and mean (SD) baseline scores, Walking Index for Spinal 
Cord Injury II (WISCI II) scores and Modified Ashworth Scale (MAS) scores for participants in 
Class 1 and 2 for the 10 meter walk test (10MWT), 6 minute walk test (6MWT) and the Timed 
Up and Go (TUG) in each group (**p<0.001 and *p<0.05 compared with Class 1 within group). 
Score  Clinical 
outcome 
Control  Lokomat (Lok)  Tizanidine (Tiz) 
Class 1  Class 2  Class 1  Class 2  Class 1  Class 2 
N 
10MWT  12  15  11  16  12  14 
6MWT  11  14  10  15  11  14 
TUG  6  20  6  20  9  15 
Baseline 
score 
10MWT  0.15 
(0.12) 
0.83 
(0.25)** 
0.13 
(0.08) 
0.80 
(0.28)** 
0.21 
(0.11) 
0.79 
(0.19)** 
6MWT  77.3 
(45.8) 
270.9 
(87.4)** 
45.7 
(28.8) 
276.5 
(91.4)** 
76.3 
(41.4) 
248.8 
(46.2)** 
TUG  104.2 
(51.0) 
27.2 
(16.6)* 
85.5 
(37.4) 
15.8 
(4.1)** 
82.4 
(22.4) 
24.5 
(15.5)* 
WISCI 
II 
10MWT  11.8 (3.3)  17.3 
(3.7)** 
9.6 (5.1)  17.4 
(3.9)** 
12.9 (2.0)  17.7 
(3.0)** 
6MWT  12.4 (3.2)  17.6 
(3.7)** 
10.6 (6.1)  17.3 
(4.0)* 
12.8 (2.2)  17.7 
(3.0)** 
TUG  12.8 (2.2)  16.3 (3.6)*  12.3 (1.6)  17.1 
(3.9)** 
11.0 (2.2)  16.5 
(4.2)** 
MAS  10MWT  2.2 (0.8)  2.1 (0.7)  2.4 (1.1)  1.8 (0.8)  1.9 (0.8)  1.6 (0.9) 
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6MWT  2.2 (0.9)  2.0 (0.7)  2.3 (1.2)  1.8 (0.9)  1.9 (0.8)  1.6 (0.9) 
TUG  1.8 (0.8)  1.7 (0.9)  2.1 (1.2)  1.8 (0.9)  2.0 (1.1)  2.1 (0.6) 
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Figures 
Figure 1. Mean (SEM) speed in the 10-meter walk test (A), distance in the 6-minute walk test 
(B) and time in the Timed up & Go test (C) for Control (black crosses), Lok (blue diamonds) and 
Tiz (red squares) groups at each timepoint (significantly different from *baseline or 
+Week 1 
(p<0.05)). 
Figure 2. Baseline speed in the 10-meter walk test (A), distance in the 6-minute walk test (B) and 
time in the Timed up & Go test (C) for participants in control (black crosses), Lok (blue 
diamonds) and Tiz (red squares) groups. Dashed black lines indicate the minimal important 
difference (MID) for each outcome measure. 
Figure 3. Mean (SEM) speed in the 10-meter walk test (A) and distance in the 6-minute walk test 
(B) for Control (black crosses), Lok (blue diamonds) and Tiz (red squares) groups and slope for 
Class 1 (dashed lines) and Class 2 (solid lines) generated by GMM-RCR. For the classes that 
showed a significant improvement with time, determined by RCR, p-values and recovery slope 
values are provided. 
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Figure 2 
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Figure 3 
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